Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options-Reference-Cited by-同舟云学术

Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options

Published:2024-05-31 Issue:11 Volume:25 Page:6063
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Mello Debora B.¹^ORCID,Mesquita Fernanda Cristina Paccola²^ORCID,Silva dos Santos Danúbia³⁴^ORCID,Asensi Karina Dutra⁴⁵^ORCID,Dias Marlon Lemos⁵^ORCID,Campos de Carvalho Antonio Carlos¹⁴⁵^ORCID,Goldenberg Regina Coeli dos Santos⁴⁵^ORCID,Kasai-Brunswick Tais Hanae¹⁴⁵^ORCID

Affiliation:

1. National Center of Structural Biology and Bioimaging, CENABIO, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

2. Regenerative Medicine Research Department, The Texas Heart Institute, Houston, TX 77030, USA

3. Center of Cellular Technology, National Institute of Cardiology, INC, Rio de Janeiro 22240-002, Brazil

4. National Institute of Science and Technology for Regenerative Medicine-REGENERA, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

5. Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

Abstract

Mesenchymal stromal cell (MSC)-based advanced therapy medicinal products (ATMPs) are being tried in a vast range of clinical applications. These cells can be isolated from different donor tissues by using several methods, or they can even be derived from induced pluripotent stem cells or embryonic stem cells. However, ATMP heterogeneity may impact product identity and potency, and, consequently, clinical trial outcomes. In this review, we discuss these topics and the need to establish minimal criteria regarding the manufacturing of MSCs so that these innovative therapeutics may be better positioned to contribute to the advancement of regenerative medicine.

Funder

Brazilian National Research Council/CNPq

Carlos Chagas Rio de Janeiro State Foundation/FAPERJ

National Center of Science and Technology for Regenerative Medicine/REGENERA

Publisher

MDPI AG

Link

https://www.mdpi.com/1422-0067/25/11/6063/pdf

Reference188 articles.

1. (2024, May 24). Advanced Therapy Medicinal Products: Overview. Available online: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview.

2. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature;Viswanathan;Cytotherapy,2019

3. Multilineage Potential of Adult Human Mesenchymal Stem Cells;Pittenger;Science,1999

4. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo;Bartholomew;Exp. Hematol.,2002

5. Mesenchymal stem cell perspective: Cell biology to clinical progress;Pittenger;NPJ Regen. Med.,2019